Compare Dishman Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs AJANTA PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA AJANTA PHARMA DISHMAN PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 25.1 23.5 106.6% View Chart
P/BV x 3.3 4.1 80.7% View Chart
Dividend Yield % 0.7 0.8 78.2%  

Financials

 DISHMAN PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
AJANTA PHARMA
Mar-19
DISHMAN PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,422 26.3%   
Low Rs129898 14.4%   
Sales per share (Unadj.) Rs197.8233.5 84.7%  
Earnings per share (Unadj.) Rs21.244.0 48.2%  
Cash flow per share (Unadj.) Rs34.752.2 66.6%  
Dividends per share (Unadj.) Rs2.009.00 22.2%  
Dividend yield (eoy) %0.80.8 102.4%  
Book value per share (Unadj.) Rs179.9255.1 70.5%  
Shares outstanding (eoy) m80.6988.02 91.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.35.0 25.6%   
Avg P/E ratio x11.926.4 45.0%  
P/CF ratio (eoy) x7.222.2 32.6%  
Price / Book Value ratio x1.44.5 30.8%  
Dividend payout %9.420.5 46.1%   
Avg Mkt Cap Rs m20,306102,081 19.9%   
No. of employees `0000.86.8 12.2%   
Total wages/salary Rs m5,3554,307 124.3%   
Avg. sales/employee Rs Th19,252.73,022.6 637.0%   
Avg. wages/employee Rs Th6,459.5633.4 1,019.8%   
Avg. net profit/employee Rs Th2,064.1569.1 362.7%   
INCOME DATA
Net Sales Rs m15,96120,554 77.7%  
Other income Rs m265211 125.9%   
Total revenues Rs m16,22620,765 78.1%   
Gross profit Rs m4,1035,664 72.4%  
Depreciation Rs m1,091721 151.3%   
Interest Rs m94412 8,141.4%   
Profit before tax Rs m2,3345,143 45.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,273 49.0%   
Profit after tax Rs m1,7113,870 44.2%  
Gross profit margin %25.727.6 93.3%  
Effective tax rate %26.724.8 108.0%   
Net profit margin %10.718.8 56.9%  
BALANCE SHEET DATA
Current assets Rs m11,01811,812 93.3%   
Current liabilities Rs m9,5173,776 252.0%   
Net working cap to sales %9.439.1 24.1%  
Current ratio x1.23.1 37.0%  
Inventory Days Days11077 142.8%  
Debtors Days Days3582 42.7%  
Net fixed assets Rs m16,30414,398 113.2%   
Share capital Rs m161175 92.0%   
"Free" reserves Rs m12,90722,277 57.9%   
Net worth Rs m14,51622,452 64.7%   
Long term debt Rs m4,1897 63,475.8%   
Total assets Rs m29,80526,962 110.5%  
Interest coverage x3.5444.3 0.8%   
Debt to equity ratio x0.30 98,182.2%  
Sales to assets ratio x0.50.8 70.2%   
Return on assets %8.914.4 61.9%  
Return on equity %11.817.2 68.4%  
Return on capital %17.523.0 76.4%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95210,682 46.4%   
Fx outflow Rs m6972,102 33.2%   
Net fx Rs m4,2558,580 49.6%   
CASH FLOW
From Operations Rs m2,7863,748 74.3%  
From Investments Rs m-1,529-2,228 68.6%  
From Financial Activity Rs m-941-1,475 63.8%  
Net Cashflow Rs m31645 700.0%  

Share Holding

Indian Promoters % 61.4 73.8 83.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 1.6 238.7%  
FIIs % 12.7 7.6 167.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.0 130.0%  
Shareholders   46,261 20,968 220.6%  
Pledged promoter(s) holding % 35.8 4.4 814.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS